Using Dual-Energy CT to Differentiate Types of Brain Bleeding in Stroke Patients
Dual Energy CT for Confirming Hemorrhagic Transformation After Thrombectomy for Patients With Acute Ischemic Stroke
This study is testing if a special type of CT scan can better tell the difference between two types of brain bleeding in stroke patients to improve their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Manitoba Academic / other |
| Drugs / interventions | abciximab, radiation |
| Locations | 1 site (Winnipeg, Manitoba) |
| Trial ID | NCT05675774 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Dual-Energy Computed Tomography (DECT) in accurately distinguishing between intracerebral hemorrhage (ICH) and contrast extravasation in patients with acute ischemic stroke (AIS) undergoing thrombolysis or thrombectomy. Participants will receive both standard single-energy CT (SECT) and DECT imaging to assess the presence of hyperdensities at 24 hours post-intervention, followed by follow-up imaging at 72 hours. The study aims to determine if DECT can improve patient care by providing more accurate diagnostic information compared to SECT.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older presenting with acute ischemic stroke who are eligible for thrombolysis or endovascular thrombectomy.
Not a fit: Patients who are not candidates for thrombolysis or endovascular thrombectomy due to various medical conditions will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and improved treatment outcomes for stroke patients experiencing complications.
How similar studies have performed: While the use of DECT in this specific context is novel, similar imaging techniques have shown promise in other studies for differentiating types of hemorrhages.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients greater than or equal to 18 years of age presenting with acute ischemic stroke (AIS) that are candidates for 1) thrombolysis (tPA) and/or 2) endovascular thrombectomy (EVT) Exclusion Criteria: * Patients who are not candidates for tPA: Intracerebral Hemorrhage on CT Ischemic Stroke within 3 months, Severe head trauma within 3 months Acute head trauma GI Malignancy or BI bleed within 21 days Coagulopathy (Platelets \<100,000/mm3, INR \>1.7, aPTT \>40s, PT\>15s) Anticoagulation (thrombin inhibitors, factor Xa inhibitors, low-molecular weight heparin) History of intracranial hemorrhage Intra-axial neoplasm Infective endocarditis Aortic Arch Dissection Patient receiving IV aspirin Patient receiving IV abciximab * Patients who are not candidates for EVT: No large vessel occlusion on CT angiogram Baseline Modified Rankin Scale \>3 No significant perfusion mismatch
Where this trial is running
Winnipeg, Manitoba
- Health Sciences Center — Winnipeg, Manitoba, Canada (Recruiting)
Study contacts
- Study coordinator: Anwer Z Siddiqi, MD, MSc.
- Email: siddiqia@myumanitoba.ca
- Phone: 780-860-2560
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.